Maury Raycroft
Stock Analyst at Jefferies
(0.62)
# 3,928
Out of 4,944 analysts
48
Total ratings
24.32%
Success rate
-15.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $328 → $384 | $432.52 | -11.22% | 2 | Jul 7, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.45 | +42.86% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $9.59 | +452.66% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $3.10 | +158.06% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.54 | +455.97% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $1.73 | +304.62% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.63 | +269.23% | 1 | Nov 18, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $6.88 | +176.16% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $3.81 | +293.70% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $20.86 | +87.01% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.81 | +640.47% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.94 | +1,085.57% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $9.34 | +1,987.79% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $8.53 | +28.96% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $21.97 | -72.69% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $19.99 | +275.19% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $6.47 | +70.02% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $10.73 | +151.63% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $2.02 | +147.52% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $52.37 | -8.34% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $11.16 | +222.58% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $6.68 | +1,471.86% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $57.33 | +200.02% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.77 | +1,596.75% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $3.92 | +5,767.35% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $11.00 | +281.82% | 3 | Nov 1, 2017 |
Alnylam Pharmaceuticals
Jul 7, 2025
Maintains: Buy
Price Target: $328 → $384
Current: $432.52
Upside: -11.22%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.45
Upside: +42.86%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $9.59
Upside: +452.66%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $3.10
Upside: +158.06%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.54
Upside: +455.97%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $1.73
Upside: +304.62%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.63
Upside: +269.23%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $6.88
Upside: +176.16%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $3.81
Upside: +293.70%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $20.86
Upside: +87.01%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.81
Upside: +640.47%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.94
Upside: +1,085.57%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $9.34
Upside: +1,987.79%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $8.53
Upside: +28.96%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $21.97
Upside: -72.69%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $19.99
Upside: +275.19%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $6.47
Upside: +70.02%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $10.73
Upside: +151.63%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $2.02
Upside: +147.52%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $52.37
Upside: -8.34%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $11.16
Upside: +222.58%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $6.68
Upside: +1,471.86%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $57.33
Upside: +200.02%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.77
Upside: +1,596.75%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $3.92
Upside: +5,767.35%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $11.00
Upside: +281.82%